Compare CQP & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CQP | WAT |
|---|---|---|
| Founded | 2003 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Laboratory Analytical Instruments |
| Sector | Utilities | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0B | 29.3B |
| IPO Year | 2006 | 1996 |
| Metric | CQP | WAT |
|---|---|---|
| Price | $66.59 | $306.67 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 7 | 17 |
| Target Price | $60.43 | ★ $379.19 |
| AVG Volume (30 Days) | 72.3K | ★ 812.8K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.05% | N/A |
| EPS Growth | N/A | ★ 0.47 |
| EPS | 0.07 | ★ 10.76 |
| Revenue | ★ $10,758,000,000.00 | $3,165,286,000.00 |
| Revenue This Year | $6.35 | $104.66 |
| Revenue Next Year | $1.27 | $10.40 |
| P/E Ratio | $956.64 | ★ $28.74 |
| Revenue Growth | ★ 23.60 | 6.99 |
| 52 Week Low | $49.53 | $275.05 |
| 52 Week High | $70.64 | $414.15 |
| Indicator | CQP | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 61.68 | 45.78 |
| Support Level | $51.48 | $305.35 |
| Resistance Level | $70.64 | $308.16 |
| Average True Range (ATR) | 1.77 | 11.47 |
| MACD | 0.48 | -2.41 |
| Stochastic Oscillator | 91.21 | 31.09 |
Cheniere Energy Partners is a liquified natural gas producer operating one facility in Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. The profit generated through those activities is split with parent and operator Cheniere Energy.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.